EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy

Peng Liu iD, Qiang Chen iD, Zhe Zhou, Yuekang Xu iD, Jinyao Li iD

Advanced Science · 2026-11 · 13 (61)

DOI: 10.1002/advs.77089 ↗

At a glance

Journal article in Advanced Science, published online on 2026-08-11. Written by Peng Liu and 4 co-authors. Institution: Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China. Major MEDLINE topics: Dendritic Cells, Cancer Vaccines, Immunotherapy, Neoplasms. 33 references. The full text is freely available (open access, CC BY 4.0). Funded by: Tianshan Talent Training Program, Major science and technology program in Xinjiang Uygur Autonomous Region, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The efficacy of dendritic cell (DC) vaccines in cancer immunotherapy is often limited by weak immunogenicity due to inefficient antigen cross‐presentation (XPT). We previously combined a calcium carbonate (CaCO 3 ) delivery system with a proteolysis‐targeting chimera (PROTAC) to enhance antigen degradation. Along this line, we developed a protein/DNA‐integrated nanoantigen platform (HpOAC) co‐loading CaCO 3 with a His‐tagged ovalbumin (O) modified with the von Hippel‐Lindau (VHL) E3 ligase‐recruiting peptide ALAPYIP (HOA) and a eukaryotic plasmid encoding O‐ALAPYIP (pOA). HpOAC promoted DC maturation and migration via Ca 2+ release. Mechanistically, HOA provided an immediate antigen source, while pOA enabled sustained expression; both underwent ALAPYIP‐mediated VHL recruitment, enhancing O ubiquitination and proteasomal degradation, thereby amplifying XPT. Consequently, HpOAC‐DCs induced strong OT‐I/OT‐II T cell proliferation in vitro. In vivo, a single immunization with HpOAC‐DCs significantly suppressed tumor growth and elicited durable antigen‐specific T helper type 1 and cytotoxic T lymphocyte responses, outperforming single‐antigen vaccines. Under a two‐dose regimen, its anti‐tumor efficacy was improved compared to non‐PROTAC and in situ antigen vaccines. Thus, we constructed a PROTAC‐enhanced, protein/DNA‐integrated DC vaccine platform that synergizes immediate and sustained antigen supply with Ca 2+ ‐mediated adjuvanticity, offering a highly promising strategy for novel DC vaccine design.

Subjects

MeSH terms (MEDLINE)

Dendritic CellsCancer VaccinesImmunotherapyNeoplasmsAnimalsProteolysis Targeting ChimeraMiceHumansNanovaccinesVaccines, DNACalcium Carbonate

Author keywords

cancer immunotherapydendritic cell vaccineprotein/DNA‐integrated nanoantigen platformproteolysis‐targeting chimera

Substances

Proteolysis Targeting ChimeraCancer VaccinesNanovaccinesVaccines, DNACalcium Carbonate

Authors and institutions

  • Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China.

ORCID profiles: Peng Liu, Qiang Chen, Yuekang Xu, Jinyao Li

Funding

  • Tianshan Talent Training Program
  • Major science and technology program in Xinjiang Uygur Autonomous Region
  • National Natural Science Foundation of China
  • Graduate Research Innovation Project of Xinjiang Uygur Autonomous Region
  • Outstanding Doctoral Innovation Project of Xinjiang University

Cite

APA

Liu, P., Chen, Q., Zhou, Z., Xu, Y., & Li, J. (2026). PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy. Advanced Science, 13(61). https://doi.org/10.1002/advs.77089

Vancouver

Liu P, Chen Q, Zhou Z, Xu Y, Li J. PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy. Advanced Science. 2026;13(61). doi:10.1002/advs.77089

BibTeX
@article{Liu2026,
  author = {Liu, Peng and Chen, Qiang and Zhou, Zhe and Xu, Yuekang and Li, Jinyao},
  title = {PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {61},
  doi = {10.1002/advs.77089}
}
Start for free →